Legal Representation
Attorney
Monte L. Falcoff/Jessica S. Sachs
USPTO Deadlines
Next Renewal Deadline
861 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-11-16)
Due Date
November 16, 2027
Grace Period Ends
May 16, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
50 events| Date | Code | Type | Description |
|---|---|---|---|
| May 4, 2024 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED |
| May 23, 2022 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB |
| May 3, 2022 | FIMP | P | FINAL DISPOSITION PROCESSED |
| May 3, 2022 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB |
| Feb 16, 2022 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Nov 16, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Aug 31, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Aug 31, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Aug 29, 2021 | GPNX | P | NOTIFICATION PROCESSED BY IB |
| Aug 23, 2021 | DOCK | D | ASSIGNED TO EXAMINER |
| Aug 11, 2021 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Aug 11, 2021 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Aug 11, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Jul 25, 2021 | EXPT | T | EXPARTE APPEAL TERMINATED |
| Jul 23, 2021 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jul 23, 2021 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Jul 23, 2021 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Jul 23, 2021 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Jul 23, 2021 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
| Jul 13, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jul 13, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jul 9, 2021 | ALIE | A | ASSIGNED TO LIE |
| May 25, 2021 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| May 10, 2021 | CHLD | M | CHANGE OF OWNER RECEIVED FROM IB |
| Apr 9, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED |
| Apr 6, 2021 | CORN | I | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED |
| Apr 3, 2021 | CRCV | M | CORRECTION TRANSACTION RECEIVED FROM IB |
| Mar 5, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED |
| Jan 26, 2021 | GNSL | S | LETTER OF SUSPENSION E-MAILED |
| Jan 26, 2021 | CNSL | R | SUSPENSION LETTER WRITTEN |
| Jan 26, 2021 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Jan 19, 2021 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Jan 19, 2021 | EXPI | T | EX PARTE APPEAL-INSTITUTED |
| Jan 19, 2021 | JURT | T | JURISDICTION RESTORED TO EXAMINING ATTORNEY |
| Jan 19, 2021 | EXAF | T | EXPARTE APPEAL RECEIVED AT TTAB |
| Oct 26, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Oct 26, 2020 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Oct 26, 2020 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jul 20, 2020 | GNFR | O | FINAL REFUSAL E-MAILED |
| Jul 20, 2020 | CNFR | R | FINAL REFUSAL WRITTEN |
| Jul 20, 2020 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Jul 14, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jul 14, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jul 14, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| May 15, 2020 | RFNT | P | REFUSAL PROCESSED BY IB |
| Apr 28, 2020 | RFRR | P | REFUSAL PROCESSED BY MPU |
| Apr 28, 2020 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Apr 11, 2020 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Apr 10, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Apr 1, 2020 | DOCK | D | ASSIGNED TO EXAMINER |
Detailed Classifications
Class 042
Study in the nature of conducting scientific feasibility studies and design of production factories and buildings; inspection of production factories and buildings for quality control and consultancy purposes; engineering; preparation of technical studies; quality control of production units in the pharmaceutical and biopharmaceutical field with a view to certification; research and development of new products for third parties; technological services regarding manufacture of biological molecules, particularly viral vectors and monoclonal antibodies, in the pharmaceutical and biopharmaceutical field; none of the foregoing in the field of cancer research or for cancer therapies or vascular targeting agents
Additional Information
Design Mark
The mark consists of the stylized wording "OXY". The "O" and "X" are in blue, and the "Y" is in blue and purple. Below this wording is the stylized wording "GENE". The "G" is in blue and purple, the "E" is in blue, purple, and orange, and the "N" and "E" are in orange. There is a stylized blue, purple, red, and orange incomplete, wavy circle to the left of the wording that extends towards the right. The color white represents background and is not claimed as a part of the mark.
Color Claim
The color(s) purple, blue, orange, and red is/are claimed as a feature of the mark.
Classification
International Classes
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"GENE"